GlassScriptPhysician profile
Sharon I Wise
NPI 1427255652
$5,099.02
in general payments reported to CMS, 2019-2025
29 companies · $735 in 2025
The $735 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $819 · 2021: $930 · 2022: $636 · 2023: $584 · 2024: $761 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,079.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,940.39 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Takeda Pharmaceuticals U.S.A., INC. | $421.66 | 2023-2025 | Entyvio |
| Pfizer INC. | $320.71 | 2019-2025 | |
| Biogen, INC. | $293.13 | 2024-2025 | Zurzuvae |
| Roche Diagnostics Corporation | $286.39 | 2019-2020 | |
| Exeltis, USA INC. | $268.06 | 2019-2025 | Slynd |
| Allergan, INC. | $192.48 | 2019-2020 | |
| Coopersurgical, INC. | $178.98 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Hologic Sales and Service, LLC | $123.51 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Organon LLC | $118.93 | 2022-2025 | Nexplanon, Jada System |
| Mylan Pharmaceuticals INC. | $117.61 | 2019-2021 | |
| Therapeuticsmd, INC. | $112.20 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $98.99 | 2022-2025 | |
| Avion Pharmaceuticals | $96.20 | 2019-2021 | |
| Exact Sciences Corporation | $70.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $68.54 | 2021 | |
| Seqirus USA INC | $57.92 | 2024-2025 | Flucelvax |
| Astellas Pharma US INC | $51.39 | 2024 | Veozah |
| Aspira Women'S Health INC | $47.54 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $40.79 | 2019-2020 | |
| Dysis Medical, INC. | $36.05 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.10 | 2020 | |
| Myovant Sciences INC. | $24.50 | 2022 | |
| Gynesonics, INC. | $19.55 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Millicent US INC | $18.04 | 2024 | Intrarosa, Femring |
| Ferring Pharmaceuticals INC. | $17.64 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.13 | 2020 | |
| Boston Scientific Corporation | $14.54 | 2019 | |
| Lupin INC. | $13.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.